A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 556
- Population
- ALL · 20 Years
- Duration
- 2019-10-07 to 2024-10-31
- Intervention
- Normal Macular Health; Early Macular Degeneration; Young Normals
- Comparator
- Not reported
- Outcomes measured
- Rod-mediated dark adaptation — Measured at baseline enrollment; Rod-mediated dark adaptation — Measured at 3 years after baseline enrollment; incident age-related macular degeneration (AMD) or progression of AMD using multimodal imaging — Measured at baseline e…; incident age-related macular degeneration (AMD) or progression of AMD using multimodal imaging — Measured at 3 years af…; Light sensitivity as measured by microperimetry and perimetry — Measured at baseline enrollment; Light sensitivity as measured by microperimetry and perimetry — Measured at 3 years after baseline enrollment; Photopic and mesopic acuity — Measured at baseline enrollment; Photopic and mesopic acuity — Measured at 3 years after baseline enrollment; Photopic and mesopic contrast sensitivity — Measured at baseline enrollment; Photopic and mesopic contrast sensitivity — Measured at 3 years after baseline enrollment
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: aging, age-related. Study type is explicitly identified as OBSERVATIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.